Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin

References

• Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9(1):10–19.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Filioussi K, Tsavaris N, et al. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23(34):8606–8612.
   PubMed Web of Science ®Google Scholar
• Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat. 2012;135(1):261–269.
   PubMed Web of Science ®Google Scholar
• Borgquist S, Tamimi RM, Chen WY, et al. Statin use and breast cancer risk in the nurses’ health study. Cancer Epidemiol Biomarkers Prev. 2016;25(1):201–206.
   PubMed Web of Science ®Google Scholar
• Manthravadi S, Shrestha A, Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. Int J Cancer. 2016;139(6):1281–1288.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Lash TL, Damkier P, et al. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol. 2014;15(10):e461–8.
   PubMed Web of Science ®Google Scholar
• Borgquist S, Bjarnadottir O, Kimbung S, et al. Statins: a role in breast cancer therapy? J Intern Med. 2018;284(4):346–357.
   PubMed Web of Science ®Google Scholar
• Kumar A, Campbell M, Benz C, et al. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol. 2006;24:2127.
   PubMed Web of Science ®Google Scholar
• Holmes MD, Chen WY. Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. Breast Cancer Res. 2012;14(2):216.
   PubMedGoogle Scholar
• Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103(19):1461–1468.
   PubMed Web of Science ®Google Scholar
• Kitzmiller JP, Sullivan DM, Phelps MA, et al. CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. Drug Metab Drug Interact. 2013;28:59–63.
   PubMedGoogle Scholar
• Sadee W. Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: statins, SLCO1B1, and CYP3A4 as an example. J Pharm Sci. 2013;102(9):2924–2929.
   PubMed Web of Science ®Google Scholar
• Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther. 2005;78(5):551–558.
   PubMed Web of Science ®Google Scholar
• Sharma P, Butters CJ, Smith V, et al. Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. Eur J Pharm Sci. 2012;47(1):244–255.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–591.
   PubMed Web of Science ®Google Scholar
• Pedersen C, Gøtzsche H, Møller J, et al. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53(4):441–449.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549.
   PubMed Web of Science ®Google Scholar
• Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group - DBCG: history, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol. 2008;47(4):497–505.
   PubMed Web of Science ®Google Scholar
• Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data resource profile: the Danish national prescription registry. Int J Epidemiol. 2017;46(3):798–798.
   PubMed Web of Science ®Google Scholar
• Erichsen R, Lash T, Hamilton-Dutoit S, et al. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51–56.
   PubMedGoogle Scholar
• Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2019 [accessed 2019 July 12]. Available from: https://www.whocc.no/filearchive/publications/2019_guidelines_web.pdf.
   Google Scholar
• Moller S, Jensen MB, Ejlertsen B, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47(4):506–524.
   PubMed Web of Science ®Google Scholar
• Jensen M-B, Laenkholm A-V, Offersen BV, et al. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016. Acta Oncol. 2018;57(1):13–18.
   PubMed Web of Science ®Google Scholar
• Schaid DJ, Batzler AJ, Jenkins GD, et al. Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata. Am J Hum Genet. 2006;79(6):1071–1080.
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Greenland S., Lash TL Case-control studies. In: Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. 3rd ed. Philadelphia (PA): Lippincott, Williams & Wilkins; 2008. p. 111–127.
   Google Scholar
• Choi HY, Bae K-S, Cho S-H, et al. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. Pharmacogenet Genomics. 2015;25(12):595–608.
   PubMed Web of Science ®Google Scholar
• Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92(1):112–117.
   PubMed Web of Science ®Google Scholar
• Xie B, Freudenheim J, Cummings S, et al. Accurate genotyping from paraffin-embedded normal tissue adjacent to breast cancer. Carcinogenesis. 2006;27(2):307–310.
   PubMed Web of Science ®Google Scholar
• Osborne RJ, Hamshere MG. A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res. 2000;60(14):3706–3712.
   PubMed Web of Science ®Google Scholar
• Miller B, Wang D, Krahe R, et al. Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet. 2003;73(4):748–767.
   PubMed Web of Science ®Google Scholar
• Frank L. EPIDEMIOLOGY: when an entire country is a cohort. Science. 2000;287(5462):2398–2399.
   PubMed Web of Science ®Google Scholar
• Riis AH, Erichsen R, Ostenfeld EB, et al. Validating registry data on statins prescriptions by blood measurements. Pharmacoepidemiol Drug Saf. 2019;28(5):609–615.
   PubMed Web of Science ®Google Scholar
• Collin LJ, Cronin-Fenton DP, Ahern TP, et al. Cohort profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) premenopausal breast cancer cohort study in Denmark. BMJ Open. 2018;8(7):e021805.
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton DP, Kjaersgaard A, Ahern TP, et al. Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study. Acta Oncol. 2017;56(9):1155–1160.
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Greenland S, Lash T. Validity in epidemiologic studies. In: Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. 3rd ed. Philadelphia (PA): Wolters Kluwer; 2008. p. 128–147.
   Google Scholar
• Gelissen IC, McLachlan AJ. The pharmacogenomics of statins. Pharmacol Res. 2014;88:99–106.
   PubMed Web of Science ®Google Scholar